Dicerna, Alnylam settle RNAi dispute

Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) said on April 20 it has resolved all litigation with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) regarding RNAi-based treatments for primary hyperoxaluria, with neither company admitting wrongdoing.

In 2015, Alnylam filed a suit in the U.S. Superior Court for the Commonwealth of Massachusetts alleging that Dicerna unlawfully obtained and used trade secrets related to Alnylam’s GalNAc RNAi conjugate delivery technology. Last year, Dicerna filed a counterclaim alleging Alnylam used "sham litigation" to “thwart Dicerna’s competitive business activities and illegally obtain for itself market dominance” in RNAi-based therapies (see BioCentury, Aug. 18, 2017)...